Evidence map›Paper›PMID 36373483›Full record

ArticleCancer medicine2023

RNA-seq and ATAC-seq analysis of CD163

Lulu Wang, Qiaoying Lv, Pengfei Wu, Shuhan Luo, Sijia Liu, Xiaojun Chen, Xuezhen Luo

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lulu WangObstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Qiaoying LvObstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Pengfei WuObstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Shuhan LuoObstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Sijia LiuObstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Xiaojun ChenObstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Xuezhen LuoObstetrics and Gynecology Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-6781-7304
Obstetrics and Gynecology Hospital of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProgestins are used as fertility-sparing regimens for young patients with stage 1A endometrioid endometrial cancer (EEC) and atypical endometrial hyperplasia (AEH). CD163

methodsThe number of infiltrating CD163

resultsIncreased CD163

conclusionsWe identified CD163

Indexed as

Carcinoma, EndometrioidEndometrial HyperplasiaEndometrial NeoplasmsCD163 AntigenChromatin Immunoprecipitation SequencingFemaleForkhead Transcription FactorsHumansMacrophagesMedroxyprogesterone AcetateProgesteroneProgestinsRNA-SeqTumor MicroenvironmentCD163 AntigenForkhead Transcription FactorsFOXF2 protein, humanMedroxyprogesterone AcetateProgesteroneProgestinsCD163+ macrophagesendometrial cancerextracellular matrixprogesterone receptorprogestin insensitivity

Identifiers

PMID36373483
PMCPMC10028121
OpenAlexW4308957812

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read47
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.